You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
TOPIC 433: A FEDERATED DATA PLATFORM FOR DEVELOPING UNBIASED BREAST IMAGING AI
SBC: FLYWHEEL EXCHANGE, LLC Topic: 433This SBIR project aims to implement a federated data platform focused on a data system to enable mammography data to be published into a federated catalog from which collaborators can execute federated analyses. It will enable hospitals and other clinical entities to make their data available for training and validation of artificial intelligence applications. The data federation will include a ra ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
SBIR PHASE I TOPIC 431, INTEGRATED CELL CULTURE CHAMBER AND FLOW GUIDE FOR POC, WALK-AWAY OPERATION FOR AUTOLOGOUS T CELL MANUFACTURING
SBC: SPATIAL SURGICAL LLC Topic: 431Surgical resection is required in approximately 80% of cancers presenting solid tumors. Despite advancing technologies, countries categorized as LMICs show an increase in incidences of various cancers. The lack of preventative screenings, and the associated infrastructure, make both identification and screening of cancers difficult. The long-term objective of this work is to build a benchtop CO2 l ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
PROJECT TITLE: AUTOMATIC TREATMENT PLANNING OF CERVICAL CANCER HIGH-DOSE RATE BRACHYTHERAPY FOR LOW-RESOURCE SETTINGS
SBC: VELOXAI LLC Topic: 431Cervical cancer is a major disease globally and 85% of the cancer burden occurs in low- and middle-income countries (LMICs). Standard of care is external-beam radiotherapy with high dose-rate brachytherapy (HDRBT). Adding brachytherapy to the treatment course improves overall survival by 12% and reduces local recurrence. HDRBT treatment planning is a complex process. Brachytherapy in low-resource ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
AN INTERPRETABLE PHYSICIAN-IN-THE-LO
SBC: MRIMATH LLC Topic: 402MRIMath technology uses Artificial Intelligence (AI) to deliver pixel-level contouring of brain tumors from surrounding healthy tissue to shorten the time it takes to plan radiation treatment, reduce variability among oncologists, and boost patient outcomes. Tumor delineation and quantification remains the weakest link in the search for accuracy in radiotherapy. Inaccuracy and variation in definin ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
TOPIC 403: DEVELOPMENT OF SPATIAL MICROPURIFICATION TECHNOLOGY
SBC: AVONEAUX MEDICAL INSTITUTE, LLC Topic: 403The tumor microenvironment (TME) comprises a mixture of cell types, including tumor cells, cancer sub-clones, metaplasia, dysplasia, desmoplasia, reactive fibroblasts, and a complex immune response. Measuring the molecular status of each cellular component within the TME is important to understanding tumor initiation and progression as well as in determining the interplay between cancer and normal ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
FY22 SBIR TOPIC 434 PHASE I- NOVEL NIST TRACEABLE IONIZATION CHAMBER FOR FLASH DOSIMETRY.
SBC: Standard Imaging Inc. Topic: 434One of the major factors limiting pre-clinical and clinical use of FLASH RT is the difficulty in measuring the FLASH irradiation parameters such as dose, dose per pulse, pulse repetition frequencies, and time structure with the available conventional radiation detectors, electrometers, and dosimetry protocols. The goal of this project is to design and construct a novel NIST-traceable ionization ch ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
TOPIC 411 CONTRACT TITLE: IMAGEDEPHI: IMAGE DE-IDENTIFICATION FOR THE ACCELERATION OF CANCER RESEARCH
SBC: KITWARE INC Topic: 411The objective of this project is to produce software that can de-identify and anonymize WSI and CT data in a reliable, efficient manner. The end result will be a software product that can be used by the pathology and medical research community to share data while minimizing the risk of exposing PHI/PII.
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
MOONSHOT- SBIR TOPIC 406, TITLE: CANCER NAVIGATION PLATFORM
SBC: Broad Axe Care Coordination LLC Topic: 406Locus Health, in this Phase II effort, will further develop and demonstrate the utility and commercial viability of its scalable, HIPAA-compliant Cancer Navigation Platform. The long-term goals of this Platform are to improve cancer patient outcomes and the efficiency and quality of patient navigation. Building on Phase I results, the project team will further develop the Platform’s patient enga ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Project Title: PRV311: A Standalone, Safe, Effective, and Affordable Treatment for Early-Stage Cervical Cancer in LMICs
SBC: PRIVO TECHNOLOGIES, LLC Topic: 431Cervical cancer (CC) has a high prevalence in low- and middle-income countries (LMICs) and remains the leading cause of cancer deaths among women, despite the remarkable improvements in prevention seen in wealthier countries. Privo Technologies intends to bridge this healthcare gap with PRV311, a nanoengineered standalone and cost-effective treatment for localized delivery of chemo-loaded nanopart ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
PHASE I-TOPIC 431- DRUG DELIVERY BY ENDOESOPHAGEAL LAVAGE (EEL) TO TREAT ESOPHAGEAL CANCER
SBC: ISOLA THERAPEUTICS INC Topic: 431Cancer is the second leading cause of death in the United States and esophageal cancer has the 6th lowest survival rate for all cancers. Systemic drug therapy is first-line therapy for widely metastatic esophageal cancer, but is limited by systemic toxicity, patient eligibility, or cost. The proprietary Isola system consists of a drug delivery catheter, tubing, heating element, and a drug lavage s ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health